- TheStreet.com•18 minutes ago
K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.
- Business Wire•3 hours ago
New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray Matter Atrophy
Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that new investigational data evaluating the effect of Aubagio® on cortical gray matter atrophy in patients with a first clinical episode suggestive of MS will be presented at the 69th American Academy of Neurology Annual Meeting.
- PR Newswire•3 hours ago
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection
BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 25, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the companies' new supplemental Biologics License Application (sBLA) for a once-monthly (every four weeks), 300 mg dose of Praluent® (alirocumab) Injection for the treatment of adults with high low-density lipoprotein (LDL) cholesterol. Praluent is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL cholesterol. The effect of Praluent on cardiovascular (CV) morbidity and mortality has not been determined.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
|Day's Range||46.19 - 46.44|
|52 Week Range||36.81 - 46.44|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||24.01|
|Dividend & Yield||1.58 (3.46%)|
|1y Target Est||N/A|